The Possible Ameliorative Effect of Hesperidin Administration in Aluminum Phosphide Induced Acute Nephrotoxicity in Adult Albino Rats

Document Type : Original Article


1 Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine- Suez Canal University, Suez Egypt

2 Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine- Suez Canal University, Suez Egypt.


Background: Aluminum phosphide (ALP) is considered as an inorganic phosphide used in controlling insects and rodents. Aluminum phosphide is highly toxic to human and animal and it can be lethal even in little amount, as it liberates a poisonous gas, phosphine under the moist conditions. Hesperidin (HSD) is a flavanone glycoside and is considered as an anti-inflammatory and antioxidant agent. Aim of the work: The present study aimed to explore the probable ameliorative effect of antioxidant hesperidin on aluminum phosphide-induced nephrotoxic changes in adult albino rats after acute exposure. Materials and methods: A thirty-six adult albino rats were divided into four groups as follows: Control group I, HSD-treated group (II): The rats received HSD (200 mg/kg b.w.). ALP-treated group (III): The rats received ALP (12 mg/kg b.w.). HSD-therapeutic group (IV): The rats received HSD (200 mg/kg b.w.) after ALP administration. Serum protein, urea, creatinine, antioxidant enzymes (GST and SOD), renal GST, MDA, SOD and lipid peroxidation markers (TBARS), were analyzed. The histological changes in kidney were assessed by using both light and electron microscopes. Results: The results revealed that HSD therapy provided marked improvement against ALP-induced acute renal toxicity which appeared in biochemical, histological and proximal convoluted tubules changes which were assessed by light and electron microscopes. Conclusion: The study concluded that HSD has an ameliorative effect in ALP induced-nephrotoxicity in adult albino rats. It increases the hope of using HSD as a new effective antidote in ALP-induced toxicity and gives an opportunity for experimental and clinical trials to evaluate its role in ALP toxicity management.
Received in original form: 30 July 2021 Accepted in a final form: 7 Augest 2021